Taken together, our study suggests that FAM83A promotes tumorigenesis of NSCLC at least partly via ERK and PI3K/Akt/mTOR pathways, making it a promising therapeutic target. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.